RCS - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

04/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230804:nRSD2825Ia&default-theme=true

RNS Number : 2825I  Physiomics PLC  04 August 2023

4 August 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company,
supporting development of oncology drugs and personalised medicine solutions,
is pleased to announce that it has been awarded a further contract by existing
client Bicycle Therapeutics ("Bicycle") that it expects to be completed over
the next six months.  The project involves modelling and the use of
bioinformatics data in support of target identification for undisclosed
Bicycle programs.

 

Physiomics CEO, Dr Jim Millen, commented: "We are delighted that, having
worked on a number of clinical stage projects with Bicycle, we are now
complementing these with a substantial project focused on earlier stage drug
development.  We look forward to working once again with Bicycle's talented
team."

 

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.  Our approach is to derive insight from all
relevant data in order to de-risk decision making and optimise design of
pre-clinical and clinical studies.  Through use of bespoke models and our
proprietary Virtual Tumour technology, the Physiomics team has informed the
development of over 100 projects, over 40 targets and 70 drugs. Clients
include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUUGRUPWGMW